Differences in Antipsychotic Prescriptions Between Centers in Young Outpatients With Schizophrenia
To the Editors: W e know that there is a gap in life expectancy between the general population and people with severe mental disorders (SMDs), 1 and therefore, major efforts are invested to improve physical health in this group. We welcome this development and will add to the discussion that an important part of these efforts is to disseminate evidence-based guidelines on psychopharmacological treatment because adverse effects of antipsychotic treatment are wellknown risk factors for many physical disorders. 2 Deliberate choice of antipsychotic treatment is essential to minimize negative impact on physical health. The Schizophrenia Patient Outcomes Research Team in the United States has made recommendations based on extensive review of literature, 3 and the British Association for Psychopharmacology has recently published guidelines considering both efficacy and risk of adverse effects from antipsychotic treatment together with handling of these. 4 In Denmark, national guidelines for antipsychotic treatment were made by an expert group based on evidence of both efficacy and safety. 5 According to these guidelines, most patients with psychotic disorders should be treated with atypical antipsychotics (amisulpride, aripiprazole, lurasidone, paliperidone, quetiapine, or risperidone) because of their favorable balance between efficacy and safety. After treatment failure on the 2 different aforementioned atypical antipsychotics, monotherapy with clozapine as a third-line drug should be considered, unless it is not a suitable option for safety reasons. In cases where clozapine is not an option, other atypical antipsychotics (olanzapine, sertindole, or ziprasidone) or typical antipsychotics (haloperidol, perphenazine, or zuclopenthixole) should be considered. Only hereafter, antipsychotic polypharmacy is considered a rational choice, to lower the psychotic symptoms. We sense, from everyday clinical practice, that this sequence is not always the case but have so far not had any real-life data in support of this. A recent paper in this journal by Edlinger et al 6 identified differences in prescription patterns between patients in inpatient and outpatient settings, and in another recent study, Joshi et al 7 documented a high degree of psychotropic polypharmacy, especially antipsychotic, among individuals with schizoaffective disorder. We have also learned some interesting aspects of antipsychotic prescription practice among outpatient units during a large-scale quality program aiming to improve general health of patients with SMDs 8, 9 and further to implement new research-generated knowledge into clinical practice. 10 In this program, detailed information on all prescriptions was collected from case records and clinical interviews. The focus of the present paper is to document antipsychotic prescription practice, because this is a potentially modifiable risk factor for physical disorders that are within the hands of us as psychiatrists.
We had access to data from 118 consecutively referred young outpatients with schizophrenia: 69 from center A and 49 from center B, both of them in the region of Central Denmark. All patients were diagnosed with schizophrenia, and the cohorts were similar in age (median age, 25 vs 23 years) and gender distribution (male, 64% vs 63%). We found remarkable differences among these patients concerning prescription patterns even though the 2 different outpatient psychosis units were organized in the same administrative region, treating similar patients and operating under the same prescription guidelines. We found that the median total dose of antipsychotic medication was significantly higher at center A at the beginning of treatment (index) (1.58 vs 1.33 defined daily dose [DDD], P = 0.02, Mann-Whitey U test [ Fig. 1, part a] ). At the final consultation within this project (follow-up), this difference in median total doses was still present, but no longer to a significant degree (1.32 vs 1.07 DDD, P = 0.52, MannWhitey U test [ Fig. 1, part a] ).
Most patients were subject to antipsychotic monotherapy as recommended, both at index (72% vs 78%) and at follow-up (58% vs 82%). We found that a higher proportion of the patients at center A were subject to antipsychotic polytherapy at index than at center B (25% vs 16%, P = 0.24, χ 2 test [ Fig. 1, part b] ). At follow-up, this difference had increased to a significant level (32% vs 6%, P < 0.01, χ 2 test [ Fig. 1,  part b] ). A small proportion of patients were not subject to antipsychotic treatment at these time points (3%-6% at index and 10%-12% at follow-up). With the "drugs of choice" from the Danish national guideline in mind, we examined the specific antipsychotics prescribed. Recommended first-and second-line antipsychotics were among the most frequent prescriptions at both centers, with aripiprazole (45%), quetiapine (44%), paliperidone (33%), and risperidone (29%) as the most commonly prescribed drugs. Amisulpride was only prescribed in 4% of patients, and lurasidone was not used in any of the patients despite the relatively low risk of metabolic disturbances. Among all patients receiving antipsychotic polytherapy, 49% of the patients received a combination of first-line drugs, 43% a combination of first-and third-line drug, and only 8% a combination of thirdline drugs. The combination of aripiprazole and quetiapine was the most common among first-line drugs, and in combinations involving third-line drugs, olanzapine was the most common. The practice of prescribing antipsychotics "PRN" ("as needed") was particularly common at center A. At both centers, quetiapine was the most commonly prescribed drug in flexible dosing (54% vs 14%). Chlorprothixene is not mentioned in the national guidelines but was used for a considerable amount of patients, mostly in flexible, low dosing (23% vs 10%). We expected this practice because quetiapine and chlorprothixene are often used in low (sub-schizophrenia) doses to treat anxiety or agitation, but the difference between centers was remarkable (74 vs 31% of patients at any time, P < 0.01, χ 2 test). These kinds of prescriptions might be a considerable and relevant hidden exposure to antipsychotic drugs: for instance, a common side effect from quetiapine is to exaggerate hyperglycemia. Very few patients were exposed to typical antipsychotics such as perphenazine or zuclopenthixole at both centers. Olanzapine was the most frequently used third-line drug (22% vs 20%), and the share of patients treated with other recommended third-choice drugs was strikingly different between centers, even though not to a significant degree: clozapine (10% vs 2%, P = 0.09, χ 2 test), sertindole (8% vs 2%, P = 0.16, χ 2 test). We have tested relevant patient data for other explanations to the differences: neither gender nor age had any predictive value. Median time since first contact with psychiatry (4.22 vs 3.45 years, P = 0.46, t test) and proportion of patients receiving antipsychotic treatment as intramuscular injection (38% vs 29%, P = 0.31, χ 2 test), which could both indicate a poorer prognosis for one of the groups, did not differ significantly between centers.
These findings suggest that there is a component of personal style, routine, or habit among the psychiatrists in the prescription of antipsychotics, because some of our findings deviate from national recommendations: in treating similar patients, one center uses higher doses and more polytherapy without any clear indication of more severely ill patients. Many patients are also exposed to third-line drugs with higher frequency of metabolic disturbances, such as olanzapine. We support keeping a continuous focus on identification and treatment of physical health in patients with SMDs, including increased attention to an optimal antipsychotic treatment to minimize the negative impact of adverse effects.
We propose continuous and mandatory postgraduate training in psychopharmacology for psychiatrists as a solution to this potential problem.
Psychopharmacology
Training for Psychiatry Residents A Pilot Iterative Quality Improvement Project
To the Editors:
T he Royal College of Physicians and Surgeons of Canada (RCPSC) recognizes that training and competency in prescribing psychotropics safely and effectively is a core requirement for all postgraduate (PG) psychiatry trainees in Canada.
1 However, recent studies report that psychiatry residents feel insufficiently prepared to prescribe psychotropic medications competently, and they experience significant anxiety and frustration to prescribe psychotropics safely. [2] [3] [4] Experts in the field suggest that a psychopharmacology curriculum is best delivered through a combination of tools such as lectures, case conferences, journal clubs, case-based learning modules, specialty clinics, and other innovative modalities.
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